Optimization of Glycosylation Distribution in the Production of Monoclonal Antibody Bio-Medicine by Full Factorial Design

doi:10.13560/j.cnki.biotech.bull.1985.2018-0782

Abstract

Abstract: This work aims to regulate the glycosylation distribution of monoclonal antibody bio-medicine,and thus which allows them to be in accord with original medicine. Full factorial design was applied to investigate the effects of 4 additives of galactose,uridine,manganese chloride and hydrolysate on the glycosylation of monoclonal antibody（mAb）. The results revealed that combined supplements of galactose,uridine and manganese chloride increased galactosylation of mAb;moreover,there was no significant impact on cell growth and antibody production. Furthermore,uridine and manganese chloride inhibited Man5 formation while excessive uridine led to a high Man5 level. Besides,protolysate not only decreased Man5 level and increased fucosylation,also enhanced cell growth. In summary,a desired target glycosylation profile was achieved after the validation was conducted through bioreactor cultivation under the optimized condition predicted by a model,thus production strategy of regulating the glycosylation of mAb during CHO cell culture process is successfully established.

Key words: CHO, monoclonal antibody, galactosylation, fucosylation, Man5, full factorial design

ZHANG Lei, YANG Mu-di, DONG Shun, LIU Ming-qiu. Optimization of Glycosylation Distribution in the Production of Monoclonal Antibody Bio-Medicine by Full Factorial Design[J]. Biotechnology Bulletin, 2019, 35(3): 217-224.

References

[1] Berger M, Kaup M, Blanchard V.Protein glycosylation and its impact on biotechnology[J]. Advances in Biochemical Engineering/Biotechnology, 2012, 127:165-185.
[2] Boyd PN, Lines AC, Patel AK.The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of campath-1h[J]. Mol Immunol, 1995, 32(17-18):1311-1318.
[3] Group TCBW.A-mab:A case study in bioprocess development[EB/OL]. CASSS, 2009:37-38.
[4] Shields RL, Lai J, Keck R, et al.Lack of fucose on human igg1 n-linked oligosaccharide improves binding to human fcgamma riii and antibody-dependent cellular toxicity[J]. J Biol Chem, 2002, 277(30):26733-26740.
[5] Alessandri L, Ouellette D, Acquah A, et al.Increased serum clearance of oligomannose species present on a human IgG1 molecule[J]. MAbs, 2012, 4(4):509-520.
[6] Goetze AM, Liu YD, Zhang Z, et al.High-mannose glycans on the fc region of therapeutic igg antibodies increase serum clearance in humans[J]. Glycobiology, 2011, 21(7):949-959.
[7] Liu H, Nowak C, Shao M, et al.Impact of cell culture on recombinant monoclonal antibody product heterogeneity[J]. Biotechnology Progress, 2016, 32(5):1103-1112.
[8] St Amand MM, Hayes J, Radhakrishnan D, et al.Identifying a robust design space for glycosylation during monoclonal antibody production[J]. Biotechnology Progress, 2016, 32(5):1149-1162.
[9] McCracken NA, Kowle R, Ouyang A. Control of galactosylated glycoforms distribution in cell culture system[J]. Biotechnology Progress, 2014, 30(3):547-553.
[10] Cabrera G, Salazar V, Montesino R, et al.Structural characterization and biological implications of sulfated n-glycans in a serine protease from the neotropical moth hylesia metabus(cramer[1775])(lepidoptera:Saturniidae)[J]. Glycobiology, 2016, 26(3):230-250.
[11] Grainger RK, James DC.Cho cell line specific prediction and control of recombinant monoclonal antibody n-glycosylation[J]. Biotechnol Bioeng, 2013, 110(11):2970-2983.
[12] St Amand MM, Radhakrishnan D, Robinson AS, et al.Identification of manipulated variables for a glycosylation control strategy[J]. Biotechnol Bioeng, 2014, 111(10):1957-1970.
[13] Gramer MJ, Eckblad JJ, Donahue R, et al.Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose[J]. Biotechnol Bioeng, 2011, 108(7):1591-1602.
[14] Pacis E, Yu M, Autsen J, et al.Effects of cell culture conditions on antibody n-linked glycosylation-what affects high mannose 5 glycoform[J]. Biotechnol Bioeng, 2011, 108(10):2348-2358.
[15] Kang S, Zhang Z, Richardson J, et al.Metabolic markers associated with high mannose glycan levels of therapeutic recombinant monoclonal antibodies[J]. J Biotechnol, 2015, 203:22-31.
[16] Gascon P.The evolving role of biosimilars in haematology-oncology:A practical perspective[J]. Ther Adv Hematol, 2015, 6(6):267-281.
[17] Hossler P, Racicot C, Chumsae C, et al.Cell culture media supplementation of infrequently used sugars for the targeted shifting of protein glycosylation profiles[J]. Biotechnology Progress, 2017, 33(2):511-522.
[18] Fan Y, Jimenez Del Val I, Muller C, et al. Amino acid and glucose metabolism in fed-batch cho cell culture affects antibody production and glycosylation[J]. Biotechnol Bioeng, 2015, 112(3):521-535.
[19] Rivinoja A, Hassinen A, Kokkonen N, et al.Elevated golgi ph impairs terminal n-glycosylation by inducing mislocalization of golgi glycosyltransferases[J]. J Cell Physiol, 2009, 220(1):144-154.
[20] Gawlitzek M, Ryll T, Lofgren J, et al.Ammonium alters n-glycan structures of recombinant tnfr-igg:Degradative versus biosynthetic mechanisms[J]. Biotechnol Bioeng, 2000, 68(6):637-646.
[21] Davami F, Eghbalpour F, Nematollahi L, et al.Effects of peptone supplementation in different culture media on growth, metabolic pathway and productivity of cho dg44 cells;a new insight into amino acid profiles[J]. Iranian Biomedical Journal, 2015, 19(4):194-205.
[22] Spearman M, Lodewyks C, Richmond M, et al.The bioactivity and fractionation of peptide hydrolysates in cultures of cho cells[J]. Biotechnology Progress, 2014, 30(3):584-593.
[23] Ho SC, Nian R, Woen S, et al.Impact of hydrolysates on monoclonal antibody productivity, purification and quality in chinese hamster ovary cells[J]. J Biosci Bioeng, 2016, 122(4):499-506.